- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01746420
Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Methodology: Randomized, single ascending dose, double-blinded, placebo controlled, multi-center study
Study Center(s): 6
Number of Subjects: 100
Diagnosis and Main Inclusion Criteria: Lateral epicondylitis; male and female subjects 21 -80 years of age
Study Drug, Dose, Regimen:
Dose A: sodium acetate buffer alone - placebo control Dose B: sodium acetate buffer + 0.45 mg rhPDGF-BB Dose C: sodium acetate buffer + 0.75 mg rhPDGF-BB Dose D: sodium acetate buffer + 1.5 mg rhPDGF-BB Dose E: sodium acetate buffer + 3.0 mg rhPDGF-BB
Duration and Route of Administration: Single administration dose by injection into the extensor carpi radialis brevis (ECRB)
Duration of Follow-up: 24 weeks (6 months) post-operative follow-up
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85023
- Arizona Research Center
-
Tucson, Arizona, Estados Unidos, 85712
- Tucson Orthopaedic Institute
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- NEA Baptist Clinic
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34209
- Coastal Orthopedics & Sports Medicine
-
Tampa, Florida, Estados Unidos, 33637
- Foundation for Orthopaedic Research and Education
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- OrthoCarolina
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject has signed the Institutional Review Board (IRB) approved Informed Consent Form specific to this study prior to enrollment
- Subject has a clinical diagnosis of lateral epicondylitis
- Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion
Subject's symptoms have persisted for at least 3 months despite conservative treatment that includes one or combinations of:
- Physical therapy
- Splinting
- Nonsteroidal antiinflammatory drug (NSAID)
- Corticosteroid injection
- Subject is independent, ambulatory, and can comply with all post-injection evaluations and visits
- Subject is 21-80 years of age and considered to be skeletally mature
Exclusion Criteria:
- Subject has undergone previous corticosteroid injection therapy to the effected elbow in less than three months prior to enrollment
- Subject has received previous Platelet Rich Plasma (PRP) injection to the affected elbow
- Subject is deemed to require a corticosteroid injection into the affected elbow during the course of the study
- Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage >10mg/day)
- Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis
Subject has a positive medical history of any of the following:
- medial epicondylitis
- radial tunnel syndrome
- carpal tunnel syndrome
- septic or gouty arthritis
- cervical radiculopathy
- trauma to the affected elbow within the past 6 weeks
- neuromuscular or musculoskeletal deficiency, which limits the ability to perform functional measurement (e.g. grip strength test)
- Subject currently has an acute infection at the injection site
- Subject has tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or are currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed rhPDGF-BB Injection treatment site
- Subject is physically or mentally compromised (e.g. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
- Subject has an allergy to yeast-derived products
- Subject has received an investigational therapy or approved therapy for investigational use within 30 days of injection procedure or during the follow-up phase of this study
- Subject is a prisoner, or is known or suspected to be transient
- Subject's condition represents a worker's compensation case
- Subject is currently involved in a health-related litigation procedure
- Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry
- Subject is pregnant, or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Placebo Control
Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
|
sodium acetate buffer (0 mg rhPDGF-BB)
|
Experimental: 0.45 mg rhPDGF-BB
Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimental: 0.75 mg rhPDGF-BB
Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimental: 1.5 mg rhPDGF-BB
Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimental: 3.0 mg rhPDGF-BB
Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Elbow Pain Assessments (VAS), Treated Subjects
Prazo: Baseline, 2, 4, 8, 12, and 24 weeks
|
Subjects were asked to report current pain level at the fusion site on a 100 mm Visual Analog Scale (with 0 being no pain and 100 being worst pain imaginable).
|
Baseline, 2, 4, 8, 12, and 24 weeks
|
Disabilities of the Arm, Shoulder and Hand (DASH), Treated Subjects
Prazo: Baseline, 4, 8, 12, and 24 weeks
|
The disabilities of the arm, shoulder and hand (DASH) questionnaire is a self-administered region-specific outcome instrument developed as a measure of self-rated upper-extremity disability and symptoms.
The DASH consists mainly of a 30-item disability/symptom scale, scored 0 (no disability) to 100.
|
Baseline, 4, 8, 12, and 24 weeks
|
Total Score Patient Rated Tennis Elbow Evaluation (PRTEE), All Treated Subjects
Prazo: Baseline, 4, 8, 12, and 24 weeks
|
The Pain and disability measured by the Patient Rated Tennis Elbow Evaluation (PRTEE) is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis (also known as "tennis elbow"). The PRTEE allows patients to rate their levels of tennis elbow pain and disability from 0 to 10, and consists of 2 subscales:
In addition to the individual subscale scores, a total score can be computed on a scale of 100 (0 = no disability), where pain and functional problems are weighted equally |
Baseline, 4, 8, 12, and 24 weeks
|
Grip Strength Test, All Treated Subjects
Prazo: Baseline, 4, 8, 12, and 24 weeks
|
Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis.
Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability).
The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis.
A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position.
Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.
|
Baseline, 4, 8, 12, and 24 weeks
|
Maximum Grip Strength, Treated Subjects
Prazo: Baseline, 4, 8, 12, and 24 weeks
|
A higher grip strength score indicates an improvement.
A positive change from baseline indicates an improvement.
Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis.
Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability).
The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis.
A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position.
Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.
|
Baseline, 4, 8, 12, and 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Edward Akelman, MD, Brown University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Ferimentos e Lesões
- Doenças musculoesqueléticas
- Doenças Musculares
- Lesões de tendão
- Tendinopatia
- Lesões nos Braços
- Tendinopatia do Cotovelo
- Cotovelo de tenista
- Efeitos Fisiológicos das Drogas
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Anticoagulantes
- Agentes Indutores de Angiogênese
- Becaplermin
Outros números de identificação do estudo
- BMTI-2010-02
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Epicondilite Lateral
-
Hospital for Special Surgery, New YorkAtivo, não recrutandoEpicondilite Lateral | Epicondilite Lateral, Cotovelo Não Especificado | Epicondilite Lateral, Cotovelo Esquerdo | Epicondilite Lateral, Cotovelo Direito | Epicondilite Lateral (Cotovelo de Tenista) Bilateral | Epicondilite Medial | Epicondilite Medial, Cotovelo Direito | Epicondilite Medial, Cotovelo...Estados Unidos
-
Mayo ClinicThe Patient Company, LLCRecrutamentoTransferência Lateral do PacienteEstados Unidos
-
The Dental Hospital of Zhejiang University School...ConcluídoEspessura da Parede LateralChina
-
Arthrex, Inc.Ativo, não recrutandoInstabilidade Lateral do TornozeloEstados Unidos
-
Washington University School of MedicineMassachusetts General HospitalSuspensoEsclerose Lateral Amiotrófica Familiar | Esclerose Lateral Amiotrófica EsporádicaEstados Unidos
-
University of OklahomaConcluídoAumento do seio da janela lateralEstados Unidos
-
Ahmed ZewailConcluídoImplante dentário | Levantamento do seio lateralEgito
-
Saint-Joseph UniversityConcluídoElevação Lateral do Seio | Complicações por operaçãoLíbano
-
University of OuluAtivo, não recrutandoFratura do Maléolo LateralFinlândia
-
Gazi UniversityRecrutamentoAnálise da marcha | Ligamento Lateral do TornozeloPeru